Second EMA Public Hearing To Focus On Quinolone, Fluoroquinolone Side Effects
The European Medicines Agency wants to hear testimonies from the public about serious side effects that have been observed in patients treated with quinolone- and fluoroquinolone-containing medicinal products.
You may also be interested in...
The European Medicines Agency has chosen 23 speakers from 55 requests made by people interested in sharing their experiences with the use of these widely-prescribed antibiotics.
Risk of disabling, potentially permanent serious side effects that can occur together will be added to Cipro, Levaquin labels along with limitation against use for some self-limiting conditions unless there are no alternative treatments.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.